Search for: "LaBelle v. LaBelle"
Results 261 - 280
of 12,213
Sorted by Relevance
|
Sort by Date
16 Dec 2008, 4:14 pm
Yesterday, the Supreme Court ruled in Altria Group v. [read post]
23 Sep 2014, 10:49 am
Solis v. [read post]
12 Mar 2009, 3:44 am
Wyeth v. [read post]
9 Sep 2008, 1:47 pm
The first case of the day will be Altria Group and Phillip Morris v. [read post]
4 May 2017, 11:08 am
Recently, in a case that should remind retailers and their suppliers to consider their First Amendment rights as they relate to the regulation of product labeling, the Eleventh Circuit Court of Appeals held in Ocheesee Creamery LLC v. [read post]
28 May 2010, 1:31 am
Kramer v. [read post]
28 May 2010, 1:31 am
Kramer v. [read post]
31 Oct 2012, 5:00 am
Watson v. [read post]
19 Jun 2014, 10:17 am
In its decision, the Court made clear that food and beverage labeling may mislead consumers even though the labeling complies with the Federal Food, Drug and Cosmetics Act (“FDCA”), and may be actionable under the Lanham Act. [read post]
29 Aug 2011, 12:30 pm
09-1039), and Actavis, Inc. v. [read post]
7 Aug 2009, 12:15 am
The complaint (full text) in Lewis v. [read post]
20 Feb 2009, 9:00 am
Feb. 12, 2009) (NO. 07-3149) A recent Seventh Circuit case demonstrated how subsequent changes to a drug warning label, could be excluded in a wrongful death action as unfairly prejudicial without considering whether the modified labels were admissible under FRE 407. [read post]
25 Oct 2010, 5:43 pm
Much of Perry v. [read post]
27 Jun 2024, 12:01 pm
TaxProf Blog Op-Ed: Moore v. [read post]
10 Apr 2017, 9:19 am
Ocheesee Creamery LLC v. [read post]
10 Apr 2017, 9:19 am
Ocheesee Creamery LLC v. [read post]
11 Oct 2023, 8:29 am
Tortilla Factory, LLC v. [read post]
10 Jul 2007, 4:58 am
Last Thursday however, the Third Department affirmed a dismissal of the class action suit finding that the plaintiff failed to state a cause of action in Baron v Pfizer, Inc., 2007 NY Slip Op 05813. [read post]
15 Feb 2016, 10:00 pm
’” And, in Jones v. [read post]
8 Apr 2013, 9:26 pm
’s fraudulent scheme to market its epilepsy drug Neurontin for off-label uses (Kaiser Foundation Health Plan, Inc. v. [read post]
